# Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

> **NCT00800462** · PHASE4 · COMPLETED · sponsor: **Toronto Rehabilitation Institute** · enrollment: 23 (actual)

## Conditions studied

- Spinal Cord Injury
- Neurogenic Detrusor Overactivity

## Interventions

- **DRUG:** Oxybutynin Cl
- **DRUG:** Trospium Cl
- **DRUG:** Darifenacin Hydrogen Bromide (HBr)

## Key facts

- **NCT ID:** NCT00800462
- **Lead sponsor:** Toronto Rehabilitation Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800462, "Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00800462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*